Management & Board of Directors

Peter Dansky has served as Chief Executive Officer and a member of the Board of Directors of Agena Bioscience since July 2014. From 2013 to 2014, Peter was CEO of iGenomX, an early stage next generation sequencing company. From 2008 to 2013, he was President of Life Technologies’ Molecular & Cell Biology and Molecular Biology Systems divisions. From 2004 to 2008, Peter served as President of Applied Biosystems’ Molecular Biology Division and General Manager of its PCR and Consumables businesses. He previously held leadership positions in marketing, sales and R&D at Arcturus Bioscience, Affymetrix, Molecular Dynamics, PerSeptive Biosystems, and Millipore. Peter holds an M.B.A. from Boston College, and M.S. and B.S. degrees in chemical engineering from Tufts University.

Terry Kinninger has over 30 years of senior executive experience in international technology companies both publicly traded and privately held in the medical diagnostics, medical device, software and information technology industries. Terry has raised over $250 million through IPO’s, private equity and debt financings, and has extensive mergers & acquisition experience with transactions totaling over $700 million. Prior to joining Agena Bioscience, Terry was CFO & COO of Estech, and prior to that CFO & Executive VP Business Development of R2 Technology. Terry has also served as COO & CFO of Bridge Medical; CFO & Senior VP Operations of MetaCreations; CFO & Senior VP Corporate Development of Delphi Information Systems; and CFO of Integral Systems and WebSideStory. Early in his career, Terry was a CPA with PricewaterhouseCoopers and holds a BS from Miami University, Ohio.

Jason Halsey joined Agena Bioscience in May 2016 as Senior Vice President, R&D and Operations. Jason most recently was Vice President of Instrument and Regulated Operations for the Life Science Solutions Group of Thermo Fisher Scientific. In this role, he oversaw the development, manufacturing, depot repair and distribution of instruments, accessories and reagents. During his 19 years with Thermo Fisher Scientific (formerly Life Technologies and Applied Biosystems), Jason held various roles in operations and R&D, and was engaged in the launch of over 50 instrument systems including the 7900, 9700, and QuantStudio. Jason holds 4 patents, 2 pending patents, and is the co-author of 2 book chapters in PCR methods. Prior to joining Life Technologies, Jason was a laboratory manager and a consulting engineer. Jason received his Bachelors of Science in Bio-Engineering from University of California at San Diego and a Masters of Business Administration from Golden Gate University.

Roman Haehn joined Agena Bioscience in December 2019 as Senior Vice President, Commercial Operations and brings more than 20 years of commercial leadership experience in medical diagnostics and life science. Prior to joining Agena Bioscience, Roman was with Luminex Corporation in multiple global roles, orchestrating commercial expansion in North America, Latin America, Europe and Asia Pacific regions. In addition to leading numerous commercial teams at Luminex, Roman also held senior positions in Global Partner Operations, facilitating growth, through key global partnerships across several market segments. For the previous 10 years, prior to Luminex, Roman held various commercial leadership roles at Ventana Medical Systems, Inc. After multiple years of consecutive revenue growth, Ventana was acquired by Roche for $3.4B. Prior to joining Ventana, Roman held regional manager and specialist roles for diagnostic and blood product organizations. Roman holds a Bachelor of Science in Human Biology, with a minor in Business from the University of Kansas.

Bob Wang joined Agena Bioscience in September 2015 as General Manager, Greater China.  Bob most recently was Marketing Director, Greater China for QIAGEN where he was responsible for leading the development of its life science and molecular diagnostic immunoassay commercial strategies. His leadership resulted in revenue growth four times higher than the market average. Prior to this, Bob was Director, Sales & Business Development for Hologic, formerly Gen-Probe, overseeing APAC M&A and China sales growth in molecular diagnostics. Bob also held senior positions in Business Development, Marketing, Sales, and Regulatory Affairs at Hologic, Life Technologies, Applied Biosystems, and the Chinese Human Genome Center, covering genomics, bioinformatics, and next generation sequencing. Bob holds an M.B.A. from the University of British Columbia and a Bachelor of Science degree in Biology from East China Normal University.

Darryl Irwin joined Agena Bioscience in May 2014, having transitioned from Sequenom Inc where he had managed the Asia Pacific Field Applications Support team from August 2006. Darryl is currently Vice President – Scientific Affairs where he leads the global custom assay development group (Assays by Agena) and strategic collaborations initiatives. Prior to Agena, Darryl was the Genotyping Business Unit Manager at the Australian Genome Research Facility, where he managed contract research projects on SNP and microsatellite genotyping technologies. With over 18 years’ experience on the MassARRAY system, Darryl has played a key role in developing novel chemistries and applications as well as mature, robust biomarker panels for disease predisposition, diagnosis, prognosis and monitoring. Darryl previously also held positions in clinical cytogenetics at the Mater Hospitals (Brisbane) and developed an ELISA based diagnostic assay for D-Dimer, a blood clot breakdown product, at Agen Biomedical Inc. Darryl holds a Bachelor of Applied Science from the Queensland University of Technology and a PhD in the area of Non-Invasive Prenatal Testing from the University of Queensland.

Dagmar Kasper joined Agena Bioscience in September 2015 as Business Manager, Clinical Diagnostics EMEA bringing with her over 15 years’ management experience in the medical device and diagnostic industries. Since 2017 she held the position as Director clinical Business Development EMEA. Prior to Agena, Dagmar was Head of Business Development for Immunodiagnostic Systems (IDS) in the United Kingdom, where she secured and managed international partnerships for strategic expansion. Prior to this, Dagmar served as General Manager for the Nordic subsidiary of IDS in Denmark, following an acquisition where she managed the transformation from a R&D and manufacturing site to a successful commercial site focusing on the clinical diagnostic market. From 2006 to 2007 Dagmar held the position as General Manager of the U.S. subsidiary of Nordic Bioscience, where she established and built the commercial sales operation. From 2001 through 2005, Dagmar held progressive marketing and sales management roles at Nordic Bioscience in Denmark. Dagmar holds a PhD in Biochemistry from University of Göttingen and is fluent in German, English, Danish and Swedish.

Michael Stringfellow currently serves as the Sr. Director of Global Customer Support at Agena, a position he has held since December 2017. Michael joined Agena in May 2017 as the Leader of the Field Applications Team before transitioning into his current role. Prior to his time at Agena he held a variety of positions at Applied Biosystems, Life Technologies and Thermo Fisher from September of 1996 to April of 2017. Michael was fortunate enough to work in regional and global roles in Field Support, Product Management, Training, Global Operations, and Technical Support during his 20 year career with Applied Biosystems which allowed him to develop a practical and comprehensive understanding of how to deliver World Class Customer Support. Before joining Thermo Fisher, Michael worked as a Cancer research associate at Myriad Genetics focused on identification of the BRCA genes. Michael is a certified Six Sigma Black Belt, a licensed Soccer coach and holds a B.S. in Molecular Biology from the University of Utah.

“I am passionate about personalized medicine, especially in the areas of oncology and pharmacogenetics. The MassARRAY provides Agena’s customers the ability to develop low-cost, extremely sensitive lab developed tests. Together we are improving patient lives and transform healthcare by delivering on the promise of personalized medicine.”

Erica Golding joined Agena Bioscience in August 2014 as the Director of Human Resources, leading the ongoing efforts of the company to effectively and efficiently manage our human capital. Prior to joining Agena Bioscience, Erica served as Head of Human Resources at Sapphire Energy, a global leader of algae cultivation technologies, based in San Diego from 2009 – 2014. Between 2006 and 2009, Erica held numerous positions in HR Departments at Amylin Pharmaceuticals, Invitrogen, and Williams Sonoma, Inc. Prior to moving into HR, Erica worked as a Litigation Consultant for a Trial Consulting firm in the bay area. Erica received B.S. degrees in Political Science and Communications from the University of California, Davis.

John Lillig has over 30 years’ experience in the management of life science and clinical diagnostics operations. Before Agena Bioscience, John served as Senior VP and Managing Director of the Brooks Life Science Systems Division of Brooks Automation. Prior to Brooks, John was the Founder, Chairman, President, and CEO of Nexus Biosystems. Before founding Nexus, John served as CTO for Discovery Partners International (DPI) and VP of DPI’s Systems Division. Prior to DPI he served as Division Manager of the Analytical Systems Division of Bio-Rad Laboratories. Earlier in his career, John held several key management positions at Beckman Instrument’s Life Science and Clinical Diagnostics operations. John received his B.S. in engineering from California Polytechnic University.

Peter Dansky has served as Chief Executive Officer and a member of the Board of Directors of Agena Bioscience since July 2014. From 2013 to 2014, Peter was CEO of iGenomX, an early stage next generation sequencing company. From 2008 to 2013, he was President of Life Technologies’ Molecular & Cell Biology and Molecular Biology Systems divisions. From 2004 to 2008, Peter served as President of Applied Biosystems’ Molecular Biology Division and General Manager of its PCR and Consumables businesses. He previously held leadership positions in marketing, sales and R&D at Arcturus Bioscience, Affymetrix, Molecular Dynamics, PerSeptive Biosystems, and Millipore. Peter holds an M.B.A. from Boston College, and M.S. and B.S. degrees in chemical engineering from Tufts University.

Deval Lashkari has over 25 years’ experience in various senior management positions in the life science industry, developing and commercializing novel technologies. Prior to Telegraph Hill Partners (THP), Deval gained corporate and business development experience through management positions at Incyte, Synteni, Operon Technologies, and Genometrix. At THP, Deval focuses on life science and diagnostics investments. Deval has represented THP on the boards of AcroMetrix, Active Motif, Althea Technologies, AltheaDx, Applied Precision, Aurora Discovery, and NEXUS Biosystems to name a few. Deval received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.

Bob Shepler has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. Bob and Matt Mackowski partnered together in 1991 to form Telegraph Hill Partners’ (THP) predecessor, focused on investing in private healthcare companies. During his career, Bob has served on numerous company boards and has represented THP on the boards of various life science and healthcare companies including Kinetikos Medical, AcroMetrix, Agena Bioscience, Aurora Discovery, Applied Precision, LDR Spine, Estech, RareCyte, Sage Labs, and Vidacare. Prior to THP, Bob was an officer with Merrill Lynch & Co. Bob received a BA from Duke University and an MBA from New York University.

Before joining Telegraph Hill Partners (THP), Paul Grossman was Head of Strategy and Corporate Development for Life Technologies, holding a similar position at Invitrogen Corporation prior to the merger with Applied Biosystems. In his tenure at Life Technologies and its legacy companies, and during his more than 20 years at Applied Biosystems, Paul held a variety of leadership and executive roles in R&D, Legal and Corporate Development teams, including spearheading the acquisition or divestment of more than 25 businesses. Paul received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. He has authored numerous scientific publications and holds more than 20 U.S. patents.